Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) CEO Todd Harris sold 500 shares of the business's stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $24.00, for a total transaction of $12,000.00. Following the completion of the transaction, the chief executive officer now owns 1,477,373 shares in the company, valued at $35,456,952. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Todd Harris also recently made the following trade(s):
- On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total transaction of $14,406.00.
- On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total transaction of $243,519.96.
- On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38.
Tyra Biosciences Stock Performance
Shares of Tyra Biosciences stock opened at $22.38 on Thursday. Tyra Biosciences, Inc. has a 52-week low of $10.38 and a 52-week high of $25.14. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of -13.32 and a beta of 1.01. The company has a fifty day moving average of $21.70 and a 200-day moving average of $18.94.
Election warning coming true…
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available on replay.
Click here to watch it now.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.09. On average, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research firms have recently issued reports on TYRA. Piper Sandler began coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $23.00 price target on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Wedbush reaffirmed an "outperform" rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, August 8th. Finally, Oppenheimer upped their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a report on Thursday, September 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Tyra Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $26.40.
View Our Latest Stock Report on TYRA
Institutional Investors Weigh In On Tyra Biosciences
A number of institutional investors have recently made changes to their positions in the business. Oppenheimer & Co. Inc. purchased a new stake in Tyra Biosciences during the 1st quarter valued at $977,000. Vanguard Group Inc. boosted its position in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock valued at $14,757,000 after buying an additional 140,833 shares during the period. Kynam Capital Management LP purchased a new stake in Tyra Biosciences during the 4th quarter valued at $4,712,000. American Century Companies Inc. boosted its position in Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock valued at $2,723,000 after buying an additional 145,346 shares during the period. Finally, Perceptive Advisors LLC boosted its position in Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock valued at $16,108,000 after buying an additional 338,208 shares during the period. Hedge funds and other institutional investors own 84.14% of the company's stock.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
